Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard of Care (SOC) for Acute Myeloid Leukemia (AML) in Canada
May 1, 2018, 00:00
10.1016/j.jval.2018.04.180
https://www.valueinhealthjournal.com/article/S1098-3015(18)30480-7/fulltext
Title :
Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard of Care (SOC) for Acute Myeloid Leukemia (AML) in Canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30480-7&doi=10.1016/j.jval.2018.04.180
First page :
Section Title :
Open access? :
No
Section Order :
1024